KALIOS.HEALTH

Written by G · Checked

No vendors · No affiliates · Nothing to sell

What we got wrong

Corrections

Every correction to a page, newest first: the date, the page, what was wrong and what it says now. Found something wrong? Send the source to kaliospeptides@proton.me.

  1. · Semax Wrong: The two Russian formulations were swapped: the 0.1% solution was given as the stroke product and the 1% as the nootropic. Now: Per the Russian label, 0.1% (50 µg per drop) is for cognitive disorders, post-stroke recovery and TIA; 1% (500 µg per drop) is for acute ischemic stroke — a tenfold difference per drop.
  2. · BPC-157 vs TB-500 vs GHK-Cu Wrong: BPC-157 was credited with a Phase II ulcerative colitis trial (NCT05765058, a dental study). Now: No such trial is registered; the page lists the Phase I registration (NCT02637284) instead.
  3. · BPC-157 Fragment Wrong: A registered Phase II colitis trial of BPC-157 was cited (NCT05765058, a dental study). Now: The only registration is a Phase I (NCT02637284) with no posted results.
  4. · BPC-157 Wrong: A Phase II ulcerative colitis trial was said to be registered on ClinicalTrials.gov (NCT05765058, a dental study). Now: No Phase II of BPC-157 is registered there; its developer’s only registration is a Phase I (NCT02637284) with no posted results.
  5. · Tesamorelin Wrong: The cognition trial ID (NCT00675506) belongs to an obesity study. Now: Baker 2012 is the SMART trial, NCT00257712.
  6. · Enclomiphene Wrong: The Phase 3 trial IDs (NCT01406964, NCT01403038) belong to unrelated studies, labelled ZA-203/ZA-204. Now: The Repros Phase 3 trials ZA-304/ZA-305 are NCT01993212 and NCT01993225.
  7. · Adipotide Wrong: The Phase I trial ID (NCT01813071) belongs to a Shigella vaccine study. Now: The MD Anderson Phase I of prohibitin targeting peptide 1 is NCT01262664 (terminated).
  8. · Melanotan I Wrong: The stroke trial ID (NCT05119296) belongs to a thyroid-cancer study. Now: Afamelanotide’s stroke proof-of-concept study is NCT04962503.
  9. · Setmelanotide Wrong: The VENTURE trial ID (NCT04966221) belongs to a COPD imaging study. Now: NCT04966741.
  10. · Pemvidutide Wrong: The IMPACT trial ID (NCT05908708) belongs to an insulin-pump study. Now: NCT05989711.
  11. · VK2735 Wrong: The VENTURE trial ID (NCT05946356) belongs to a fibromyalgia study. Now: NCT06068946.
  12. · Survodutide Wrong: The SYNCHRONIZE-1 and -2 trial IDs (NCT06066879, NCT06066892) belong to unrelated studies. Now: NCT06066515 and NCT06066528.
  13. · N-Acetyl-Epithalon Wrong: The Adv Gerontol 2002 cohort paper was credited to Korkushko, Khavinson, Shatilo et al., at 2002;9:80-87. Now: It is Khavinson and Morozov, Adv Gerontol 2002;10:74-84.
  14. · Flow State Stack Wrong: The Khavinson mortality cohort was listed under Epitalon. Now: It is listed under Epithalamin, the extract the cohort used.
  15. · Thymalin Wrong: The Gist called Thymalin’s partner in the elderly study “Epitalon (the pineal extract)”, and the study a trial. Now: The partner was Epithalamin, a pineal extract; the paper doesn’t describe randomization.
  16. · Epithalon Wrong: The 266-patient mortality data were presented as Epithalon’s. Now: They come from Epithalamin, the pineal extract Epithalon was modelled on, given with or without Thymalin.
  17. · Vilon Wrong: The Khavinson 2003 elderly cohort was described as 266 people randomized to Vilon + Epithalon. Now: It followed 266 people given Thymalin and Epithalamin gland extracts, not Vilon, and doesn’t describe randomization; the data table and dosing notes say so.
  18. · FDA PCAC tracker Wrong: The tracker’s summary line and search description said the July 23–24, 2026 meeting voted on 12 peptides. Now: It is the PCAC review of 12 peptides, 7 of which were voted on July 23–24, 2026; the other 5 are due before the end of February 2027.
  19. · Tirzepatide Wrong: The shortage was said to be resolved in October 2024. Now: FDA’s October 2, 2024 decision was sent back by a court and reaffirmed on December 19, 2024; the compounders’ grace periods ended in March 2025.
  20. · Semaglutide vs Tirzepatide Wrong: The page said compounding discretion ended once Novo Nordisk and Eli Lilly “declared” their shortages resolved, in 2024–early 2025, and that the telehealth channels were active through 2023 and early 2024. Now: FDA made both determinations (tirzepatide December 19, 2024; semaglutide February 21, 2025), and its grace periods for compounders ended between February and May 2025; the telehealth channels ran until then.
  21. · Orforglipron Wrong: The timeline started Foundayo at 3 mg and described dose escalation within 3–36 mg, which are trial doses; the data table listed only the trial doses. Now: The label starts at 0.8 mg and steps up through 2.5, 5.5, 9 and 14.5 to a 17.2 mg maximum; the 3–36 mg doses are labelled as the trials’.
  22. · Tesamorelin Wrong: The Egrifta SV row gave a 1.4 mg vial mixed with 2.1 mL (~1 mg/1.5 mL); the label dose was given as 2 mg; Egrifta WR was said to have launched in January 2025 as a room-temperature-stable version with unchanged dosing. Now: Egrifta SV is a 2 mg vial mixed with 0.5 mL, and the 1.4 mg dose is 0.35 mL. Egrifta WR (11.6 mg vial, 1.28 mg = 0.16 mL daily for 7 days) was approved March 25, 2025 and available from September 2025.
  23. · Bromantane Wrong: The page said some US 503A pharmacies dispense bromantane under “USP-grade bulk powder frameworks”. Now: We couldn’t verify that any pharmacy does, and it has no basis: not FDA-approved, no USP monograph, on no 503A list or in any nomination category.
  24. · 5-Amino-1MQ Wrong: The page said 503A compounding pharmacies dispense 5-Amino-1MQ under a “USP grade bulk powder framework” whose legality was merely uncertain. Now: It is in no FDA list or nomination category, is in no approved drug and has no USP monograph, so compounding it meets none of the conditions of section 503A or 503B.
  25. · Glutathione Wrong: The page named “503A / 503B compounding pharmacies” without saying on what basis. Now: Glutathione is in Category 1 of both FDA lists, so pharmacies and outsourcing facilities compound it under interim policies; it is on neither final bulks list.
  26. · VIP Wrong: The page said VIP is available from 503A and 503B compounding pharmacies. Now: It is in FDA’s 503A Category 1 (interim policy); it has no 503B pathway.
  27. · Enclomiphene Wrong: The page said enclomiphene is compounded by 503A and 503B pharmacies. Now: It is in FDA’s 503A Category 1 (interim policy); it is on no 503B list or category, so outsourcing facilities have no pathway.
  28. · Sermorelin Wrong: Geref was said to be withdrawn “for commercial reasons”, and sermorelin “legally compoundable by 503A and 503B pharmacies under traditional compounding law”. Now: FDA withdrew Geref’s approvals in 2009 at the maker’s request because it was no longer marketed, not for safety. 503A pharmacies compound it as a component of an approved drug; outsourcing facilities only under FDA’s Category 1 interim policy.
  29. · Cagrilintide Wrong: CagriSema’s FDA review carried an April 2026 date, and the decision was “anticipated within 1–2 years”. Now: Novo Nordisk filed CagriSema in December 2025; as of September 28, 2026 FDA hasn’t decided, and Novo expects a decision in Q4 2026.
  30. · CagriSema Wrong: “Under FDA review” carried an April 2026 date, and the decision was “anticipated within 1–2 years”. Now: Novo Nordisk filed the application in December 2025; as of September 28, 2026 FDA hasn’t decided, and Novo expects a decision in Q4 2026.
  31. · hCG Wrong: The page said 503A compounding of hCG was “limited” since the 2020 transition, that access to compounded hCG had improved and some state boards had restored it, and listed compounded multi-dose hCG among the products. Now: Since March 23, 2020 hCG products are licensed biologics, and FDA’s position is that biologics can’t be compounded under 503A or 503B; pharmacies may only mix, dilute or repackage a licensed product under FDA’s 2018 guidance. No hCG biosimilar is approved.
  32. · Wolverine Stack Wrong: TB-500 was described as a 43-amino-acid peptide with a 2–3-day half-life, a BPC-157 safety study was labelled as TB-500’s, and TB-500 purity problems were blamed on the size of a 43-amino-acid synthesis. Now: TB-500 is the thymosin β4 17–23 fragment, with no measured human half-life; the parent protein’s studies are labelled as the parent’s.
  33. · BPC-157 vs TB-500 vs GHK-Cu Wrong: TB-500 was described as full-length thymosin β4 (4,963 Da, Phase III results), and the fragment sold as TB-500 was called a mislabelled product. Now: TB-500 is the seven-amino-acid fragment; full-length Tβ4 is its parent and the molecule in the trials, and the COA mass (889 vs 4,963 Da) tells them apart.
  34. · TB-500 Wrong: TB-500 was described as full-length thymosin β4 (43 amino acids, 4,921 Da, a 2–3-day half-life, banned by WADA since 2011), with gray-market vials “nearly always” the full protein; it cited a dry-eye Phase 3 miss (SEER-3) that isn’t on record, a heart-attack pilot whose trial never enrolled, and horse repair studies we couldn’t find. Now: TB-500 is Ac-LKKTETQ, residues 17–23 of thymosin β4 (889 Da), as FDA and doping-control labs define it: no human studies, no published half-life, named by WADA since 2018. The human trials are labelled as the parent protein’s, and the TB-500 Fragment page is folded into this one.
  35. · Stack pair pages Wrong: The literature tables on 307 pair pages repeated the wrong links and author lists from the compound pages. Now: They carry the same corrections.
  36. · Zuclomiphene Wrong: 3 reference links opened a different paper than the one cited; 2 citations named the wrong authors, title, journal or year. Now: Each link opens the paper the reference names, with its details as PubMed indexes them.
  37. · Wolverine Stack Wrong: 2 reference links opened a different paper than the one cited. Now: Each link opens the paper the reference names.
  38. · Waglerin-1 Wrong: Waglerin was said to be first isolated in 1992 by Schmidt and Weinstein, citing a 1992 paper on its synaptic effects under the wrong authors and journal; ten other citations named the wrong authors or journal. Now: It was first isolated and sequenced in 1991 (Weinstein, Schmidt and colleagues, Toxicon), now in the references; the 1992 paper is Aiken et al., Pharmacol Toxicol. Authors and journals match PubMed.
  39. · VK2735 Wrong: One reference link opened a different paper than the one cited. Now: Each link opens the paper the reference names.
  40. · VIP Wrong: 5 reference links opened a different paper than the one cited. Now: Each link opens the paper the reference names.
  41. · Vilon Wrong: 6 reference links opened a different paper than the one cited. Now: Each link opens the paper the reference names.
  42. · Vialox Wrong: 3 reference links opened a different paper than the one cited; 2 citations named the wrong authors, title, journal or year. Now: Each link opens the paper the reference names, with its details as PubMed indexes them.
  43. · Vesugen Wrong: 6 reference links opened a different paper than the one cited. Now: Each link opens the paper the reference names.
  44. · Vesilute Wrong: 6 reference links opened a different paper than the one cited. Now: Each link opens the paper the reference names.
  45. · Triptorelin Wrong: 5 reference links opened a different paper than the one cited. Now: Each link opens the paper the reference names.
  46. · Tripeptide-29 Wrong: 2 reference links opened a different paper than the one cited; 2 citations named the wrong authors, title, journal or year. Now: Each link opens the paper the reference names, with its details as PubMed indexes them.
  47. · Tirzepatide Wrong: One reference link opened a different paper than the one cited. Now: Each link opens the paper the reference names.
  48. · Thymulin Wrong: 7 reference links opened a different paper than the one cited; 5 citations named the wrong authors, title, journal or year. Now: Each link opens the paper the reference names, with its details as PubMed indexes them.
  49. · Thymosin Alpha-1 Wrong: Three hepatitis studies were misdescribed: Poo 2008 as a randomized trial in 352 untreated hepatitis C patients, Chien 1998 as a comparison with interferon, and the Zhang 2009 meta-analysis as 13 trials in 1,034 patients. Eight links opened other papers; three references named the wrong authors or journal. Now: Poo 2008 was open-label, in 40 patients who had failed interferon (21.1% sustained response); Chien 1998 compared Tα1 with no treatment; Zhang 2009 pooled 8 trials in 583 patients. Each link opens the paper named.
  50. · Thymalin Wrong: 3 reference links opened a different paper than the one cited. Now: Each link opens the paper the reference names.
  51. · Thymagen Wrong: 2 reference links opened a different paper than the one cited; 3 citations named the wrong authors, title, journal or year. Now: Each link opens the paper the reference names, with its details as PubMed indexes them.
  52. · Testagen Wrong: 4 reference links opened a different paper than the one cited. Now: Each link opens the paper the reference names.
  53. · Tesofensine Wrong: A 2009 letter to The Lancet was presented as the journal’s expression of concern about the tesofensine trial; three other citations had the wrong link or authors. Now: The Lancet’s expression of concern about the tesofensine trial report is from April 2013 (PMID 23561987); the 2009 items are two letters. Each link opens the paper named.
  54. · Tesamorelin Wrong: 3 reference links opened a different paper than the one cited. Now: Each link opens the paper the reference names.
  55. · TB-500 Wrong: 3 reference links opened a different paper than the one cited. Now: Each link opens the paper the reference names.
  56. · TB-500 Fragment 17-23 Wrong: 3 reference links opened a different paper than the one cited. Now: Each link opens the paper the reference names.
  57. · Syn-Coll Wrong: 2 reference links opened a different paper than the one cited. Now: Each link opens the paper the reference names.
  58. · Syn-Ake Wrong: One citation named the wrong authors, title, journal or year. Now: Each link opens the paper the reference names, with its details as PubMed indexes them.
  59. · SS-31 Wrong: 3 reference links opened a different paper than the one cited. Now: Each link opens the paper the reference names.
  60. · SNAP-8 Wrong: 4 reference links opened a different paper than the one cited. Now: Each link opens the paper the reference names.
  61. · SLU-PP-332 Wrong: One reference link opened a different paper than the one cited. Now: Each link opens the paper the reference names.
  62. · Setmelanotide Wrong: One reference link opened a different paper than the one cited; 2 citations named the wrong authors, title, journal or year. Now: Each link opens the paper the reference names, with its details as PubMed indexes them.
  63. · Sermorelin Wrong: 5 reference links opened a different paper than the one cited. Now: Each link opens the paper the reference names.
  64. · Semax Wrong: One citation named the wrong authors, title, journal or year. Now: Each link opens the paper the reference names, with its details as PubMed indexes them.
  65. · Selank Wrong: 3 citations named the wrong authors, title, journal or year. Now: Each link opens the paper the reference names, with its details as PubMed indexes them.
  66. · Rigin Wrong: 10 reference links opened a different paper than the one cited; 3 citations named the wrong authors, title, journal or year. Now: Each link opens the paper the reference names, with its details as PubMed indexes them.
  67. · Retatrutide Wrong: 2 citations named the wrong authors, title, journal or year. Now: Each link opens the paper the reference names, with its details as PubMed indexes them.
  68. · PT-141 Wrong: 2 reference links opened a different paper than the one cited; 2 citations named the wrong authors, title, journal or year. Now: Each link opens the paper the reference names, with its details as PubMed indexes them.
  69. · Pramlintide Wrong: 7 reference links opened a different paper than the one cited. Now: Each link opens the paper the reference names.
  70. · Pinealon Wrong: 7 reference links opened a different paper than the one cited. Now: Each link opens the paper the reference names.
  71. · Pentapeptide-18 Wrong: 10 reference links opened a different paper than the one cited. Now: Each link opens the paper the reference names.
  72. · Pemvidutide Wrong: 3 reference links opened a different paper than the one cited. Now: Each link opens the paper the reference names.
  73. · PEG-MGF Wrong: 5 reference links opened a different paper than the one cited. Now: Each link opens the paper the reference names.
  74. · Pancragen Wrong: 6 reference links opened a different paper than the one cited. Now: Each link opens the paper the reference names.
  75. · Palmitoyl Dipeptide-6 Wrong: One reference link opened a different paper than the one cited; one citation named the wrong authors, title, journal or year. Now: Each link opens the paper the reference names, with its details as PubMed indexes them.
  76. · Pal-GHK Wrong: 2 reference links opened a different paper than the one cited. Now: Each link opens the paper the reference names.
  77. · Pal-AHK Wrong: One reference link opened a different paper than the one cited. Now: Each link opens the paper the reference names.
  78. · P21 Wrong: 8 reference links opened a different paper than the one cited. Now: Each link opens the paper the reference names.
  79. · Oxytocin Wrong: 10 reference links opened a different paper than the one cited. Now: Each link opens the paper the reference names.
  80. · Ovagen Wrong: 7 reference links opened a different paper than the one cited; 2 citations named the wrong authors, title, journal or year. Now: Each link opens the paper the reference names, with its details as PubMed indexes them.
  81. · Orforglipron Wrong: 3 reference links opened a different paper than the one cited. Now: Each link opens the paper the reference names.
  82. · Nonapeptide-1 Wrong: 3 reference links opened a different paper than the one cited; 5 citations named the wrong authors, title, journal or year. Now: Each link opens the paper the reference names, with its details as PubMed indexes them.
  83. · Neurokinin A Wrong: 2 reference links opened a different paper than the one cited; 4 citations named the wrong authors, title, journal or year. Now: Each link opens the paper the reference names, with its details as PubMed indexes them.
  84. · Nesfatin-1 Wrong: 4 reference links opened a different paper than the one cited. Now: Each link opens the paper the reference names.
  85. · NAD+ Wrong: The trial of nicotinamide riboside in mild cognitive impairment was credited to Vreones 2023 and said to show a trend toward cognitive benefit. Now: It is Orr 2024: 20 patients for 10 weeks; blood NAD+ rose 2.6-fold and cognition didn’t change.
  86. · N-Acetyl Semax Wrong: 7 reference links opened a different paper than the one cited; one citation named the wrong authors, title, journal or year. Now: Each link opens the paper the reference names, with its details as PubMed indexes them.
  87. · N-Acetyl Selank Wrong: 9 reference links opened a different paper than the one cited; 2 citations named the wrong authors, title, journal or year. Now: Each link opens the paper the reference names, with its details as PubMed indexes them.
  88. · N-Acetyl-Epithalon Wrong: One reference link opened a different paper than the one cited. Now: Each link opens the paper the reference names.
  89. · MOTS-c Wrong: 2 reference links opened a different paper than the one cited; 2 citations named the wrong authors, title, journal or year. Now: Each link opens the paper the reference names, with its details as PubMed indexes them.
  90. · MK-677 Wrong: 4 reference links opened a different paper than the one cited. Now: Each link opens the paper the reference names.
  91. · Mito Stack Wrong: 3 reference links opened a different paper than the one cited; one citation named the wrong authors, title, journal or year. Now: Each link opens the paper the reference names, with its details as PubMed indexes them.
  92. · MGF Wrong: 10 reference links opened a different paper than the one cited. Now: Each link opens the paper the reference names.
  93. · Methylene Blue Wrong: 7 reference links opened a different paper than the one cited. Now: Each link opens the paper the reference names.
  94. · Melanotan II Wrong: The teenage FAMMM case report behind the mole-change warning was credited to Cardones 2009, and four references named the wrong authors or journal. Now: It is Sivyer 2012 (Dermatol Pract Concept). Authors and journals match PubMed; each link opens the paper named.
  95. · Melanotan I Wrong: 6 reference links opened a different paper than the one cited. Now: Each link opens the paper the reference names.
  96. · Mazdutide Wrong: 3 reference links opened a different paper than the one cited. Now: Each link opens the paper the reference names.
  97. · LL-37 Wrong: 2 reference links opened a different paper than the one cited. Now: Each link opens the paper the reference names.
  98. · Livagen Wrong: 5 reference links opened a different paper than the one cited. Now: Each link opens the paper the reference names.
  99. · Liraglutide Wrong: One reference link opened a different paper than the one cited; one citation named the wrong authors, title, journal or year. Now: Each link opens the paper the reference names, with its details as PubMed indexes them.
  100. · KPV Wrong: 3 reference links opened a different paper than the one cited. Now: Each link opens the paper the reference names.
  101. · KLOW Stack Wrong: One reference link opened a different paper than the one cited. Now: Each link opens the paper the reference names.
  102. · Kisspeptin Wrong: 5 reference links opened a different paper than the one cited; one citation named the wrong authors, title, journal or year. Now: Each link opens the paper the reference names, with its details as PubMed indexes them.
  103. · Ipamorelin Wrong: 4 reference links opened a different paper than the one cited. Now: Each link opens the paper the reference names.
  104. · Insulin Wrong: 2 reference links opened a different paper than the one cited. Now: Each link opens the paper the reference names.
  105. · IGF-1 DES Wrong: 12 reference links opened a different paper than the one cited. Now: Each link opens the paper the reference names.
  106. · Humanin Wrong: The central insulin-sensitizing study was cited as Muzumdar, Diabetes 2009, and eleven other links opened unrelated papers. Now: It is Muzumdar et al., PLoS One 2009. Links that could be matched to their paper now open it; five that couldn’t are listed in the report.
  107. · HGH Wrong: 9 reference links opened a different paper than the one cited. Now: Each link opens the paper the reference names.
  108. · HGH Fragment 176-191 Wrong: 6 reference links opened a different paper than the one cited. Now: Each link opens the paper the reference names.
  109. · Hexarelin Wrong: 6 reference links opened a different paper than the one cited; 12 citations named the wrong authors, title, journal or year. Now: Each link opens the paper the reference names, with its details as PubMed indexes them.
  110. · HCG Wrong: 4 reference links opened a different paper than the one cited. Now: Each link opens the paper the reference names.
  111. · GW-0742 Wrong: 4 reference links opened a different paper than the one cited. Now: Each link opens the paper the reference names.
  112. · Gonadorelin Wrong: 8 reference links opened a different paper than the one cited. Now: Each link opens the paper the reference names.
  113. · Glutathione Wrong: 3 reference links opened a different paper than the one cited. Now: Each link opens the paper the reference names.
  114. · GLOW Stack Wrong: 4 reference links opened a different paper than the one cited. Now: Each link opens the paper the reference names.
  115. · GHRP-6 Wrong: 7 reference links opened a different paper than the one cited. Now: Each link opens the paper the reference names.
  116. · GHRP-2 Wrong: 4 reference links opened a different paper than the one cited. Now: Each link opens the paper the reference names.
  117. · GHK-Cu Wrong: 10 reference links opened a different paper than the one cited; one citation named the wrong authors, title, journal or year. Now: Each link opens the paper the reference names, with its details as PubMed indexes them.
  118. · GHK-Cu Fragment Wrong: 7 reference links opened a different paper than the one cited. Now: Each link opens the paper the reference names.
  119. · GHK Basic Wrong: 6 reference links opened a different paper than the one cited. Now: Each link opens the paper the reference names.
  120. · GH Stack Wrong: 5 reference links opened a different paper than the one cited. Now: Each link opens the paper the reference names.
  121. · FOXO4-DRI Wrong: 2 reference links opened a different paper than the one cited; 4 citations named the wrong authors, title, journal or year. Now: Each link opens the paper the reference names, with its details as PubMed indexes them.
  122. · Flow State Stack Wrong: One reference link opened a different paper than the one cited; 3 citations named the wrong authors, title, journal or year. Now: Each link opens the paper the reference names, with its details as PubMed indexes them.
  123. · Epithalon Wrong: 3 reference links opened a different paper than the one cited. Now: Each link opens the paper the reference names.
  124. · Enclomiphene Citrate Wrong: One citation named the wrong authors, title, journal or year. Now: Each link opens the paper the reference names, with its details as PubMed indexes them.
  125. · Eloralintide Wrong: 4 reference links opened a different paper than the one cited; 2 citations named the wrong authors, title, journal or year. Now: Each link opens the paper the reference names, with its details as PubMed indexes them.
  126. · Dulaglutide Wrong: 9 reference links opened a different paper than the one cited. Now: Each link opens the paper the reference names.
  127. · DSIP Wrong: The review titled “a still unresolved riddle” was credited to Kastin and Akerstrom, 2003, with a link to another paper; four other citations had the wrong link or authors. Now: It is Kovalzon and Strekalova, J Neurochem 2006, and the summary follows its abstract. Each link opens the paper named.
  128. · DS5 Wrong: One reference link opened a different paper than the one cited. Now: Each link opens the paper the reference names.
  129. · Dihexa Wrong: One reference link opened a different paper than the one cited. Now: Each link opens the paper the reference names.
  130. · Cortagen Wrong: 8 reference links opened a different paper than the one cited. Now: Each link opens the paper the reference names.
  131. · CJC-1295 Wrong: 5 reference links opened a different paper than the one cited; 2 citations named the wrong authors, title, journal or year. Now: Each link opens the paper the reference names, with its details as PubMed indexes them.
  132. · Chonluten Wrong: 8 reference links opened a different paper than the one cited. Now: Each link opens the paper the reference names.
  133. · Cerebrolysin Wrong: 2 reference links opened a different paper than the one cited. Now: Each link opens the paper the reference names.
  134. · Cartalax Wrong: 7 reference links opened a different paper than the one cited. Now: Each link opens the paper the reference names.
  135. · Cardiogen Wrong: 9 reference links opened a different paper than the one cited; one citation named the wrong authors, title, journal or year. Now: Each link opens the paper the reference names, with its details as PubMed indexes them.
  136. · CagriSema Wrong: 2 citations named the wrong authors, title, journal or year. Now: Each link opens the paper the reference names, with its details as PubMed indexes them.
  137. · Cagrilintide Wrong: 2 reference links opened a different paper than the one cited; 4 citations named the wrong authors, title, journal or year. Now: Each link opens the paper the reference names, with its details as PubMed indexes them.
  138. · Bronchogen Wrong: 9 reference links opened a different paper than the one cited. Now: Each link opens the paper the reference names.
  139. · Bromantane Wrong: 2 reference links opened a different paper than the one cited. Now: Each link opens the paper the reference names.
  140. · BPC-157 Fragment Wrong: One citation named the wrong authors, title, journal or year. Now: Each link opens the paper the reference names, with its details as PubMed indexes them.
  141. · Argireline Wrong: One reference link opened a different paper than the one cited; 2 citations named the wrong authors, title, journal or year. Now: Each link opens the paper the reference names, with its details as PubMed indexes them.
  142. · ARA-290 Wrong: 8 reference links opened a different paper than the one cited; one citation named the wrong authors, title, journal or year. Now: Each link opens the paper the reference names, with its details as PubMed indexes them.
  143. · AOD-9604 Wrong: One reference link opened a different paper than the one cited; 3 citations named the wrong authors, title, journal or year. Now: Each link opens the paper the reference names, with its details as PubMed indexes them.
  144. · AICAR Wrong: 2 reference links opened a different paper than the one cited. Now: Each link opens the paper the reference names.
  145. · AHK-Cu Wrong: One reference link opened a different paper than the one cited. Now: Each link opens the paper the reference names.
  146. · Adipotide Wrong: 5 reference links opened a different paper than the one cited. Now: Each link opens the paper the reference names.
  147. · Adamax Wrong: 5 reference links opened a different paper than the one cited. Now: Each link opens the paper the reference names.
  148. · 5-Amino-1MQ Wrong: 6 reference links opened a different paper than the one cited. Now: Each link opens the paper the reference names.
  149. · BPC-157 vs TB-500 vs GHK-Cu Wrong: 2 reference links opened a different paper than the one cited. Now: Each link opens the paper the reference names.
  150. · Follistatin-344 Wrong: Six reference links opened other papers; the two Mendell gene-therapy trials were swapped (Becker muscular dystrophy 2015, inclusion body myositis 2017); the NEJM case report was paraphrased loosely; the WADA category was given as S2 (peptide hormones and growth factors). Now: Links, trials and the NEJM wording now match the papers; WADA S4.3, myostatin-binding proteins: the 2026 Prohibited List names follistatin there.